CHA Biotech Exits Soliders Investment, Focuses on CGT, AI-enabled Healthcare, CDMO

CHA Biotech Group announced on the 13th that it has sold its entire stake in Soliders Investment, the group’s venture-capital arm focused on biomedicine and healthcare, to JW Holdings.

The sale covers all holdings held by CHA Biotech Group subsidiaries and related entities in Soliders Investment: 46.5% in CHA BioTech, 29.6% in ChaCareS, 20.0% in CMG Pharmaceuticals, and 3.9% in Seongkwang Medical Foundation. The total transaction amount is 30.6 billion won.

The group described the move as a measure to improve capital efficiency and to reorganize its portfolio around core businesses while sharpening its focus on future-growth areas.

With the proceeds, CHA Biotech Group plans to reinforce its core activities in cell and gene therapy (CGT) research and development and in its contract development and manufacturing organization (CDMO) business to bolster its global bio-infrastructure capabilities. It also aims to accelerate expansion in digital healthcare by leveraging artificial intelligence and data technologies.

A CHA Biotech Group official said the company is restructuring around three core pillars—CGT, AI-enabled healthcare, and life sciences—and will wind down investments that are not closely aligned with these areas to support a long-term growth strategy.

Soliders Investment operates as the group’s venture-capital arm, and the sale to JW Holdings represents a transfer of these holdings away from CHA Biotech Group to a separate investor.

For U.S. readers, the move highlights how a major Korean biotech conglomerate is reallocating capital toward high-growth fields such as CGT and digital health, potentially affecting future collaboration, supply chains, and investment flows between Korean biopharma entities and American partners in research, development, and manufacturing.